B se BETA drugs ......
Credit report presenting the estimates for the results due ....😀😀
#OncoDaily #pharmaceuticalindustry
Insights and Opportunity Costs in Applying Spatial Biology to Study the Tumor Microenvironment
Cancer Discovery AACR OncoAlert OncoDaily Michael Angelo Stanford Pathology #MedEd #MedX #Oncology
doi.org/10.1158/2159-8…
RELATIVITY-060 did not meet its primary end point of improved ORR in patients with LAG-3 expression ≥1% when relatlimab was added to nivolumab + chemotherapy compared with nivolumab + chemotherapy. Journal of Clinical Oncology ASCO #ASCO24 #Oncology OncoAlert OncoDaily #MedEd #MedX #GITwitter
👀Is W&W approach suitable for those with ncCR? Unknowns:What % of ncCRs convert to cCRs? How can we predict these patients? Average time from ncCR to cCR? How long to wait and when to act? JAMA Oncology Yakup Ergün Arndt Vogel OncoDaily Enes Erul MD doi:10.1001/jamaoncol.2024.0856
10th CRS + HIPEC.
8 discharged, 2 recovering.
7 months of PSM program.
Only center/team in Nepal offering CRS + HIPEC.
Possible in LMIC.
Bhaktapur Cancer Hospital
ESMO - Eur. Oncology OncoDaily Peritoneal Surface Oncology Group International European Society of Surgical Oncology (ESSO) ISSPP
Thank you Robin Thambudorai, Dr Bipradas Roy and Tata Medical Center
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Cancer Discovery AACR ESMO - Eur. Oncology OncoAlert OncoDaily #oncology #pharmacology #RASG12C #NRASG12C #Cancer #Cancer Research
aacrjournals.org/cancerdiscover…
📢 I am thrilled to share our latest study just published in Cancers MDPI
✅Royal Marsden Hospital (RMH) score predicts cancer survival beyond clinical trials
💥Promising tool for real-world patient care
A huge thank you to Deniz Can Guven 🙏
OncoAlert OncoDaily
Authors proposed a precision-driven approach for patient selection to identify successful combinations of immunotherapy to improve outcomes for patients with cancer
Vivek Subbiah, MD Aakash Desai, MD, MPH #Cancer #immunotherapy OncoAlert OncoDaily #ASCO24
doi.org/10.1002/cncr.3…
RAS G12C Inhibitors: Three Birds with One Stone
Cancer Discovery AACR OncoAlert OncoDaily Sandra Misale
Johns Hopkins Kimmel Cancer Center Johns Hopkins Medicine #MedEd #MedX
doi.org/10.1158/2159-8…
These results provide evidence for the clinical relevance of including genomic features into the transplantation decision making process, allowing personalizing the hazards and effectiveness of HSCT in patients with MDS. Journal of Clinical Oncology ASCO ESMO - Eur. Oncology OncoAlert @OncoDaily #Oncology
Precision treatment in advanced hepatocellular carcinoma
Cancer Cell Arndt Vogel #HCC #liverCancer #carcinoma #PrecisionMedicine #MedEd #medx #Oncology OncoAlert OncoDaily #news
cell.com/cancer-cell/ab…
🌟 Week 2 of #GlobalAccessToAntiGD2
Based on ANBL0032 survival benefit of antiGD2 in high-risk NB EFS increased to 66% vs. 46%!
🌍 Many kids lack this lifesaving treatment.
Let's get anti-GD2 on the #WHO Essential Medicines List. Immune Oncology Research Institute OncoDaily World Health Organization (WHO)
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
Cancer Discovery AACR OncoAlert Ethan Cerami Dana-Farber Dana-Farber Data Science OncoDaily #MedEd #MedX #Oncology
doi.org/10.1158/2159-8…
